HBW Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Commercialization Phase Brings New Challenges To Nanotech Industry

This article was originally published in The Rose Sheet

Executive Summary

Increased industry/government collaboration is needed in the field of nanotechnology to move from the research & development phase to the comercialization phase, speakers told the President's Council of Advisors on Science and Technology (PCAST) during a June 25 meeting in Arlington, Va

You may also be interested in...



Nanotech regulation

A new report commissioned by the Project on Emerging Nanotechnologies (PEN) at the Woodrow Wilson International Center for Scholars stresses the need for regulatory oversight of nanotechnology and provides a "roadmap" for the Environmental Protection Agency to handle the challenges of the science. In the report, author J. Clarence Davies lays out an agenda designed to create an "effective oversight system" to "minimize any adverse effects of nano-materials," identifying a need for change within the EPA in areas of science, program integration, personnel, international activities and program evaluation, according to a May 23 release. The 76-page report outlines 25 steps that EPA, the government, the U.S. National Nanotechnology Initiative and the nanotechnology industry should take to improve oversight. "This new report seeks to encourage ... an intelligent oversight approach that empowers EPA and promotes investment and innovation in new nanotechnology products and processes," states PEN Director David Rejeski...

Fraud Discovery Institute Asks Waxman To Address Lead In Herbalife Products

FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation

Fraud Discovery Institute Asks Waxman To Address Lead In Herbalife Products

FDA should issue a public health alert to warn consumers about potential health risks that may result from use of Herbalife dietary supplements and should remove the company's products from the market, pending further investigation of lead contamination, according to Christopher Grell, an attorney whose firm specializes in ephedra and dietary supplement litigation
UsernamePublicRestriction

Register

RS014813

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel